Companion actives, working doses, and evidence notes
This reluctance is likely to be at least partially attributable to the fact that, until recently, all GLP-1RAs were available as subcutaneous (s.c.) injections, given twice daily (exenatide [13]), once daily (lixisenatide [14] and liraglutide [15]), or once weekly (semaglutide [16], dulaglutide [17], and exenatide extended release [18]), a route that may be less preferable to some patients compared with oral administration [1, 19]
In the skin, GHK-Cu acts as a signal peptide, encouraging natural processes vital for skin health
The COVID-19 pandemic disrupted the CDCs data collection, which is why the most recent figures are from 2017-18
The field has limited understanding of how heterogeneity and differences in genetic susceptibility across different ethnic groups and countries contribute to T1D (240242)
Both Eli Lilly and Novo Nordisk assert that widespread compounding poses safety concerns and undermines their intellectual property rights
